X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs PFIZER - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE PFIZER CADILA HEALTHCARE/
PFIZER
 
P/E (TTM) x 32.1 31.2 102.8% View Chart
P/BV x 6.0 5.0 120.2% View Chart
Dividend Yield % 0.8 0.7 120.8%  

Financials

 CADILA HEALTHCARE   PFIZER
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
PFIZER
Mar-16
CADILA HEALTHCARE/
PFIZER
5-Yr Chart
Click to enlarge
High Rs4602,724 16.9%   
Low Rs3051,611 18.9%   
Sales per share (Unadj.) Rs92.1440.9 20.9%  
Earnings per share (Unadj.) Rs14.848.7 30.4%  
Cash flow per share (Unadj.) Rs18.575.8 24.4%  
Dividends per share (Unadj.) Rs3.2015.00 21.3%  
Dividend yield (eoy) %0.80.7 120.9%  
Book value per share (Unadj.) Rs68.0462.9 14.7%  
Shares outstanding (eoy) m1,023.7445.75 2,237.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.9 84.5%   
Avg P/E ratio x25.844.5 58.0%  
P/CF ratio (eoy) x20.728.6 72.4%  
Price / Book Value ratio x5.64.7 120.2%  
Dividend payout %21.630.8 70.1%   
Avg Mkt Cap Rs m391,58199,163 394.9%   
No. of employees `00016.92.9 583.4%   
Total wages/salary Rs m15,0022,758 544.0%   
Avg. sales/employee Rs Th5,594.56,981.7 80.1%   
Avg. wages/employee Rs Th890.1954.5 93.3%   
Avg. net profit/employee Rs Th899.9771.1 116.7%   
INCOME DATA
Net Sales Rs m94,29520,170 467.5%  
Other income Rs m1,286857 150.0%   
Total revenues Rs m95,58121,028 454.6%   
Gross profit Rs m19,0364,310 441.7%  
Depreciation Rs m3,7501,239 302.7%   
Interest Rs m4505 8,653.8%   
Profit before tax Rs m16,1223,923 410.9%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-399 -3.0%   
Tax Rs m1,2891,794 71.8%   
Profit after tax Rs m15,1682,228 680.9%  
Gross profit margin %20.221.4 94.5%  
Effective tax rate %8.045.7 17.5%   
Net profit margin %16.111.0 145.6%  
BALANCE SHEET DATA
Current assets Rs m60,22316,299 369.5%   
Current liabilities Rs m53,0587,594 698.7%   
Net working cap to sales %7.643.2 17.6%  
Current ratio x1.12.1 52.9%  
Inventory Days Days7065 107.0%  
Debtors Days Days8826 342.4%  
Net fixed assets Rs m72,9848,622 846.5%   
Share capital Rs m1,024458 223.8%   
"Free" reserves Rs m68,57620,722 330.9%   
Net worth Rs m69,60021,180 328.6%   
Long term debt Rs m24,68425 98,736.0%   
Total assets Rs m152,20729,137 522.4%  
Interest coverage x36.8755.5 4.9%   
Debt to equity ratio x0.40 30,046.2%  
Sales to assets ratio x0.60.7 89.5%   
Return on assets %10.37.7 133.9%  
Return on equity %21.810.5 207.2%  
Return on capital %17.919.0 94.4%  
Exports to sales %00.1 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA12 0.0%   
Imports (cif) Rs mNA3,526 0.0%   
Fx inflow Rs m21,28052 41,200.4%   
Fx outflow Rs m10,874140 7,768.3%   
Net fx Rs m10,406-88 -11,780.8%   
CASH FLOW
From Operations Rs m13,4953,436 392.7%  
From Investments Rs m-29,103-6,991 416.3%  
From Financial Activity Rs m23,158-619 -3,742.4%  
Net Cashflow Rs m7,556-4,174 -181.0%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 8.3 7.5 110.7%  
FIIs % 5.9 4.9 120.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 23.7 46.4%  
Shareholders   44,069 85,207 51.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   STRIDES SHASUN LTD  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  ELDER PHARMA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 23, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - ELDER PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS